Ginsenoside Rk2, a dehydroprotopanaxadiol saponin, alleviates alcoholic liver disease via regulating NLRP3 and NLRP6 inflammasome signaling pathways in mice

Jian Zou,Rujie Yang,Ruibing Feng,Jiayue Liu,Jian-Bo Wan
DOI: https://doi.org/10.1016/j.jpha.2023.05.005
IF: 14.026
2023-05-14
Journal of Pharmaceutical Analysis
Abstract:Highlights • Rk2, a rare ginsenoside, exhibits profound therapeutic effects on ALD in mice. • Acting as NLRP3 inhibitor, Rk2 ameliorates alcohol-induced liver inflammation. • Rk2 exerts an inhibitory effect on NLRP3 through binding to NLRP3 protein. • Rk2 alleviates alcohol-induced intestinal barrier dysfunction by enhancing colonic NLRP6. • Rk2 enhances intestinal NLRP6 inflammasome by modulating fecal taurine level. Heavy alcohol consumption results in alcoholic liver disease (ALD) with inadequate therapeutic options. Here, we first report the potential beneficial effects of ginsenoside Rk2, a rare dehydroprotopanaxadiol saponin isolated from streamed ginseng, against alcoholic liver injury in mice. Chronic-plus-single-binge ethanol feeding caused severe liver injury, as manifested by significantly elevated serum aminotransferase levels, hepatic histological changes, increased lipid accumulation, oxidative stress, and inflammation in the liver. These deleterious effects were alleviated by the treatment with ginsenoside Rk2 (5 and 30 mg/kg). Acting as an NLRP3 inhibitor, Rk2 ameliorates alcohol-induced liver inflammation by inhibiting NLRP3 inflammasome signaling in the liver. Meanwhile, the treatment with Rk2 alleviated the alcohol-induced intestinal barrier dysfunction via enhancing NLRP6 inflammasome in the intestine. Our findings indicate that Rk2 is a promising agent for the prevention and treatment of ALD and other NLPR3-driven diseases. Graphical abstract Download : Download high-res image (353KB) Download : Download full-size image
pharmacology & pharmacy
What problem does this paper attempt to address?